Addressing overtreatment in breast cancer: The doctors' dilemma

Cancer

Volumn 119, Issue 20, 2013, Pages 3584-3588

  Katz, Steven J ^a   Morrow, Monica ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; EVIDENCE BASED MEDICINE; HUMAN; MASTECTOMY; MEDICAL DECISION MAKING; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; RISK BENEFIT ANALYSIS; SENTINEL LYMPH NODE BIOPSY; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT PLANNING;

BREAST NEOPLASMS; FEMALE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; TIME-TO-TREATMENT; UNNECESSARY PROCEDURES;

EID: 84883115159     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28260     Document Type: Review

References (51)

1. Glass AG, Lacey J Jr, Carreon JD, Hoover RN,. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007; 99: 1152-1161. (Pubitemid 47233065)
2. Vladeck BC, Rice T,. Market failure and the failure of discourse: facing up to the power of sellers. Health Aff (Millwood). 2009; 28: 1305-1315.
3. Ciatto S,. The overdiagnosis nightmare: a time for caution. BMC Womens Health. 2009; 9: 34.
4. Virnig BA, Wang SY, Shamilyan T, Kane RL, Tuttle TM,. Ductal carcinoma in situ: risk factors and impact of screening. J Natl Cancer Inst Monogr. 2010; 2010: 113-116.
5. Anderson WF, Reiner AS, Matsuno RK, Pfeiffer RM,. Shifting breast cancer trends in the United States. J Clin Oncol. 2007; 25: 3923-3929. (Pubitemid 47485304)
6. Esserman L, Shieh Y, Thompson I,. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009; 302: 1685-1692.
7. Peto R, Davies C, Godwin J, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012; 379: 432-444.
8. Davies C, Godwin J, Gray R, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378: 771-784.
9. Early Breast Cancer Trialists' Collaborative Group WC, Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer mortality: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378: 1707-1716.
10. Katz SJ, Morrow M,. The challenge of individualizing treatments for patients with breast cancer. JAMA. 2012; 307: 1379-1380.
11. Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996; 14: 1982-1992.
12. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996; 88: 1529-1542. (Pubitemid 26374506)
13. Katz SJ, Hawley S,. From policy to patients and back: surgical treatment decision-making for patients with breast cancer. Health Aff (Millwood). 2007; 26: 761-769.
14. Nichols HB, Berrington de González AB, Lacey Jr. JV, Rosenberg PS, Anderson WF,. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011; 29: 1564-1569.
15. Tuttle TM, Jarosek S, Habermann EB, Yee D, Yuan J, Virnig BA,. Omission of radiation therapy after breast-conserving surgery in the United States. Cancer. 2012; 118: 2004-2013.
16. Soulos PR, Yu JB, Roberts KB, et al. Assessing the impact of a cooperative group trial on breast cancer care in the Medicare population. J Clin Oncol. 2012; 30: 1601-1607.
17. Giordano SH,. Radiotherapy in older women with low-risk breast cancer: why did practice not change? J Clin Oncol. 2012; 30: 1577-1578.
18. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus Tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004; 351: 971-977. (Pubitemid 39166260)
19. Giuliano AE, Morrow M, Duggal S, Julian TB,. Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer? Clin Exp Metastasis. 2012; 29: 687-692.
20. Rossari JR, Metzger-Filho O, Paesmans M, et al. Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence. J Oncol. 2012; 2012: 417-573.
21. Adjuvant! Online. http://www.adjuvantonline.com.
22. Baum M, Ravdin PM,. Decision-making in early breast cancer: guidelines and decision tools. Eur J Cancer. 2002; 38: 745-749. (Pubitemid 34280317)
23. Davidson NE, Levine M,. Breast cancer consensus meetings: vive la difference? J Clin Oncol. 2002; 20: 1719-1720. (Pubitemid 34273258)
24. Eifel P, Axelson JA, Costa J, et al. The National Institutes of Health Consensus Development Conference: Adjuvant Therapy for Breast Cancer. Paper presented at: NIH Consensus Development Conference2000; Bethesda, MD. J Natl Cancer Inst. 2001; 93: 979-989.
25. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Clin Oncol. 2001; 19: 3817-3827. (Pubitemid 32880060)
26. Gelber R, Boldhirsch A, Thurlimann B,. Adjuvant Therapy of Primary Breast Cancer: Proceedings of the 7th International Conference. St. Gallen, Switzerland: Harcourt; 2001.
27. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009; 27: 5700-5706.
28. Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol. 2009; 27: 5693-5699.
29. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-1684. (Pubitemid 41464706)
30. Hassett MJ, Silver SM, Hughes ME, et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol. 2012; 30: 2218-2226.
31. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351: 2817-2826. (Pubitemid 40051905)
32. National Comprehensive Cancer Network. www.nccn.org/professionals/ physician-gls/pdf/breast.pdf. Accessed September 24, 2012.
33. Hassett MJ, Silver SM, Hughes ME, et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol. 2012; 30: 2218-2226.
34. Hornberger J, Alvarado MD, Rebecca C, Gutierrez HR, Yu TM, Gradishar WJ,. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-state breast cancer: a systematic review. J Natl Cancer Inst. 2012; 104: 1068-1079.
35. Sparano J,. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006; 7: 347-350. (Pubitemid 44717771)
36. Hawley ST, Griggs JJ, Hamilton AS, et al. Decision involvement and receipt of mastectomy among racially and ethnically diverse breast cancer patients. J Natl Cancer Inst. 2009; 101: 1337-1347.
37. Katz SJ, Lantz PM, Janz NK, et al. Patient involvement in surgical treatment decisions for breast cancer. J Clin Oncol. 2005; 23: 5526-5533.
38. Botteri E, Bagnardi V, Rotmensz N, et al. Analysis of local and regional recurrences in breast cancer after conservative surgery. Ann Oncol. 2010; 21: 723-728.
39. Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer. J Clin Oncol. 2009; 27: 2466-2473.
40. Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D, Sabri S,. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 2011; 29: 2852-2858.
41. Adkins FC, Gonzalez-Angulo AM, Lei X, et al. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol. 2011; 18: 3164-3173.
42. Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011; 29: 3885-3891.
43. Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Melgaard H, Overgaard J,. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008; 26: 1419-1426.
44. Janz NK, Mujahid MS, Hawley ST, et al. Racial/ethnic difference in quality of life after diagnosis of breast cancer. J Cancer Surviv. 2009; 3: 212-222.
45. Duric V, Stockler M,. Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile. Lancet Oncol. 2001; 2: 691-697. (Pubitemid 33085815)
46. Sweeney KJ, Ryan E, Canney M, O'Daly BJ, Kerin MJ,. Justifying adjuvant chemotherapy in breast cancer: a survey of women and healthcare professionals. Eur J Surg Oncol. 2007; 33: 838-842. (Pubitemid 47279050)
47. King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for cocntralateral prophylactic mastectomy. J Clin Oncol. 2011; 29: 2158-2164.
48. Lostumbo L, Carbine NE, Wallace J,. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010; 11 (CD002748).
49. Institute of Medicine. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academy of Sciences; 2011.
50. Abernethy AP, Ahmad A, Zafar SY, Wheeler JL, Reese JB, Lyerly HK,. Electronic patient-reported data capture as a foundation of rapid learning cancer care. Med Care. 2010; 48 (6 suppl): S32-S38.
51. Abernethy AP, Etheredge LM, Ganz PA, et al. Rapid-learning system for cancer care. J Clin Oncol. 2010; 28: 4268-4274.